Re: OTC Expert & Grey Market Restrictions
in response to
by
posted on
Nov 22, 2022 11:19AM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
The thing is, Zenith CC does publically disclose financial and other information on SEDAR if that is the only issue with regards to Rule 15c2-11
Koo